Cargando…

2855. Respiratory Syncytial Virus Neutralizing Antibodies in Cord Blood and Serum from Infants up to 2 Years of Age in a Multinational Prospective Study

BACKGROUND: Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections (LRTI) during infancy worldwide. High cord blood (CB) concentrations of anti-RSV neutralizing antibody (nAb) may attenuate, delay, or prevent infant infection. We report RSV A and B nAb conce...

Descripción completa

Detalles Bibliográficos
Autores principales: Domachowske, Joseph B, Bianco, Veronique, Ceballos, Ana, Cousin, Luis, D’Andrea, Ulises, Dieussaert, Ilse, Englund, Janet A, Gandhi, Sanjay, Haars, Gerco, Jose, Lisa, Klein, Nicola, Marie. Langley, Joanne, Leach, Amanda, Madhi, Shabir A, Maleux, Koen, Lien-Anh Nguyen, Thi, Puthanakit, Thanyawee, Silas, Peter, Stoszek, Sonia K, Tangsathapornpong, Auchara, Teeratakulpisarn, Jamaree, Virta, Miia, Zaman, Khalequ
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808773/
http://dx.doi.org/10.1093/ofid/ofz359.160
_version_ 1783461817626918912
author Domachowske, Joseph B
Bianco, Veronique
Ceballos, Ana
Cousin, Luis
D’Andrea, Ulises
Dieussaert, Ilse
Englund, Janet A
Gandhi, Sanjay
Haars, Gerco
Jose, Lisa
Klein, Nicola
Marie. Langley, Joanne
Leach, Amanda
Madhi, Shabir A
Maleux, Koen
Lien-Anh Nguyen, Thi
Puthanakit, Thanyawee
Silas, Peter
Stoszek, Sonia K
Tangsathapornpong, Auchara
Teeratakulpisarn, Jamaree
Virta, Miia
Zaman, Khalequ
author_facet Domachowske, Joseph B
Bianco, Veronique
Ceballos, Ana
Cousin, Luis
D’Andrea, Ulises
Dieussaert, Ilse
Englund, Janet A
Gandhi, Sanjay
Haars, Gerco
Jose, Lisa
Klein, Nicola
Marie. Langley, Joanne
Leach, Amanda
Madhi, Shabir A
Maleux, Koen
Lien-Anh Nguyen, Thi
Puthanakit, Thanyawee
Silas, Peter
Stoszek, Sonia K
Tangsathapornpong, Auchara
Teeratakulpisarn, Jamaree
Virta, Miia
Zaman, Khalequ
author_sort Domachowske, Joseph B
collection PubMed
description BACKGROUND: Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections (LRTI) during infancy worldwide. High cord blood (CB) concentrations of anti-RSV neutralizing antibody (nAb) may attenuate, delay, or prevent infant infection. We report RSV A and B nAb concentrations in CB and serum from a birth cohort at different time points through 2 years of age. METHODS: Between 2013 and 2017, newborns from 8 countries were studied prospectively from birth to 2 years of age (NCT01995175). CB was collected at birth for the entire cohort. A subcohort of children was randomly assigned to have one blood sample collected again at either 2, 4, 6, 12, 18, or 24 months of age. Sera were analyzed for RSV A and B nAb concentrations by serum neutralization assay. Active surveillance was used to identify LRTIs during the 2-year follow-up as previously reported. RESULTS: In total, 2,401 newborns were enrolled and followed up. >99% of infants had detectable CB RSV A and B nAb. Geometric mean antibody titers (GMTs) varied by country, but were overall higher for RSV B than for RSV A (327 vs. 251; Figure 1). The lowest GMTs were seen from CB sera collected from South African newborns (197 RSV A, 255 RSV B); Canadian newborns had the highest RSV A GMT (383), while Hondurans had the highest RSV B GMT (460). 1380 infants provided follow-up serum nAb results as part of the subcohort (Figure 2). Dramatic waning of GMTs was evident, with a ~3-fold drop in GMTs at 2 months of age, and an additional ~2-fold drop between 2 and 4 months of age. At 6 and 12 months of age, 71% and 50% of infants had RSV A nAb and GMTs were at a nadir of 14. At 6, 12, and 18 months of age, RSV B nAb was detected in 98%, 69%, and 63% of infants, respectively. The RSV B nAb nadir GMT of 20 was observed at 12 months of age, while the 6- and 18-month RSV B nAb GMTs were 30 and 31, respectively. A total of 1,017 LRTIs were identified during the 2-year study period; of which, 94 (9%) were caused by RSV A and 132 (13%) by RSV B. Associations between CB nAb levels and RSV infection will be presented. CONCLUSION: Neutralizing Ab to RSV A and B was present at birth in infants from 8 countries, and waned over time. GMTs were at a nadir at 6 to 12 months of age. Funding. GlaxoSmithKline Biologicals SA. [Image: see text] [Image: see text] DISCLOSURES: All Authors: No reported Disclosures.
format Online
Article
Text
id pubmed-6808773
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68087732019-10-28 2855. Respiratory Syncytial Virus Neutralizing Antibodies in Cord Blood and Serum from Infants up to 2 Years of Age in a Multinational Prospective Study Domachowske, Joseph B Bianco, Veronique Ceballos, Ana Cousin, Luis D’Andrea, Ulises Dieussaert, Ilse Englund, Janet A Gandhi, Sanjay Haars, Gerco Jose, Lisa Klein, Nicola Marie. Langley, Joanne Leach, Amanda Madhi, Shabir A Maleux, Koen Lien-Anh Nguyen, Thi Puthanakit, Thanyawee Silas, Peter Stoszek, Sonia K Tangsathapornpong, Auchara Teeratakulpisarn, Jamaree Virta, Miia Zaman, Khalequ Open Forum Infect Dis Abstracts BACKGROUND: Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections (LRTI) during infancy worldwide. High cord blood (CB) concentrations of anti-RSV neutralizing antibody (nAb) may attenuate, delay, or prevent infant infection. We report RSV A and B nAb concentrations in CB and serum from a birth cohort at different time points through 2 years of age. METHODS: Between 2013 and 2017, newborns from 8 countries were studied prospectively from birth to 2 years of age (NCT01995175). CB was collected at birth for the entire cohort. A subcohort of children was randomly assigned to have one blood sample collected again at either 2, 4, 6, 12, 18, or 24 months of age. Sera were analyzed for RSV A and B nAb concentrations by serum neutralization assay. Active surveillance was used to identify LRTIs during the 2-year follow-up as previously reported. RESULTS: In total, 2,401 newborns were enrolled and followed up. >99% of infants had detectable CB RSV A and B nAb. Geometric mean antibody titers (GMTs) varied by country, but were overall higher for RSV B than for RSV A (327 vs. 251; Figure 1). The lowest GMTs were seen from CB sera collected from South African newborns (197 RSV A, 255 RSV B); Canadian newborns had the highest RSV A GMT (383), while Hondurans had the highest RSV B GMT (460). 1380 infants provided follow-up serum nAb results as part of the subcohort (Figure 2). Dramatic waning of GMTs was evident, with a ~3-fold drop in GMTs at 2 months of age, and an additional ~2-fold drop between 2 and 4 months of age. At 6 and 12 months of age, 71% and 50% of infants had RSV A nAb and GMTs were at a nadir of 14. At 6, 12, and 18 months of age, RSV B nAb was detected in 98%, 69%, and 63% of infants, respectively. The RSV B nAb nadir GMT of 20 was observed at 12 months of age, while the 6- and 18-month RSV B nAb GMTs were 30 and 31, respectively. A total of 1,017 LRTIs were identified during the 2-year study period; of which, 94 (9%) were caused by RSV A and 132 (13%) by RSV B. Associations between CB nAb levels and RSV infection will be presented. CONCLUSION: Neutralizing Ab to RSV A and B was present at birth in infants from 8 countries, and waned over time. GMTs were at a nadir at 6 to 12 months of age. Funding. GlaxoSmithKline Biologicals SA. [Image: see text] [Image: see text] DISCLOSURES: All Authors: No reported Disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6808773/ http://dx.doi.org/10.1093/ofid/ofz359.160 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Domachowske, Joseph B
Bianco, Veronique
Ceballos, Ana
Cousin, Luis
D’Andrea, Ulises
Dieussaert, Ilse
Englund, Janet A
Gandhi, Sanjay
Haars, Gerco
Jose, Lisa
Klein, Nicola
Marie. Langley, Joanne
Leach, Amanda
Madhi, Shabir A
Maleux, Koen
Lien-Anh Nguyen, Thi
Puthanakit, Thanyawee
Silas, Peter
Stoszek, Sonia K
Tangsathapornpong, Auchara
Teeratakulpisarn, Jamaree
Virta, Miia
Zaman, Khalequ
2855. Respiratory Syncytial Virus Neutralizing Antibodies in Cord Blood and Serum from Infants up to 2 Years of Age in a Multinational Prospective Study
title 2855. Respiratory Syncytial Virus Neutralizing Antibodies in Cord Blood and Serum from Infants up to 2 Years of Age in a Multinational Prospective Study
title_full 2855. Respiratory Syncytial Virus Neutralizing Antibodies in Cord Blood and Serum from Infants up to 2 Years of Age in a Multinational Prospective Study
title_fullStr 2855. Respiratory Syncytial Virus Neutralizing Antibodies in Cord Blood and Serum from Infants up to 2 Years of Age in a Multinational Prospective Study
title_full_unstemmed 2855. Respiratory Syncytial Virus Neutralizing Antibodies in Cord Blood and Serum from Infants up to 2 Years of Age in a Multinational Prospective Study
title_short 2855. Respiratory Syncytial Virus Neutralizing Antibodies in Cord Blood and Serum from Infants up to 2 Years of Age in a Multinational Prospective Study
title_sort 2855. respiratory syncytial virus neutralizing antibodies in cord blood and serum from infants up to 2 years of age in a multinational prospective study
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808773/
http://dx.doi.org/10.1093/ofid/ofz359.160
work_keys_str_mv AT domachowskejosephb 2855respiratorysyncytialvirusneutralizingantibodiesincordbloodandserumfrominfantsupto2yearsofageinamultinationalprospectivestudy
AT biancoveronique 2855respiratorysyncytialvirusneutralizingantibodiesincordbloodandserumfrominfantsupto2yearsofageinamultinationalprospectivestudy
AT ceballosana 2855respiratorysyncytialvirusneutralizingantibodiesincordbloodandserumfrominfantsupto2yearsofageinamultinationalprospectivestudy
AT cousinluis 2855respiratorysyncytialvirusneutralizingantibodiesincordbloodandserumfrominfantsupto2yearsofageinamultinationalprospectivestudy
AT dandreaulises 2855respiratorysyncytialvirusneutralizingantibodiesincordbloodandserumfrominfantsupto2yearsofageinamultinationalprospectivestudy
AT dieussaertilse 2855respiratorysyncytialvirusneutralizingantibodiesincordbloodandserumfrominfantsupto2yearsofageinamultinationalprospectivestudy
AT englundjaneta 2855respiratorysyncytialvirusneutralizingantibodiesincordbloodandserumfrominfantsupto2yearsofageinamultinationalprospectivestudy
AT gandhisanjay 2855respiratorysyncytialvirusneutralizingantibodiesincordbloodandserumfrominfantsupto2yearsofageinamultinationalprospectivestudy
AT haarsgerco 2855respiratorysyncytialvirusneutralizingantibodiesincordbloodandserumfrominfantsupto2yearsofageinamultinationalprospectivestudy
AT joselisa 2855respiratorysyncytialvirusneutralizingantibodiesincordbloodandserumfrominfantsupto2yearsofageinamultinationalprospectivestudy
AT kleinnicola 2855respiratorysyncytialvirusneutralizingantibodiesincordbloodandserumfrominfantsupto2yearsofageinamultinationalprospectivestudy
AT marielangleyjoanne 2855respiratorysyncytialvirusneutralizingantibodiesincordbloodandserumfrominfantsupto2yearsofageinamultinationalprospectivestudy
AT leachamanda 2855respiratorysyncytialvirusneutralizingantibodiesincordbloodandserumfrominfantsupto2yearsofageinamultinationalprospectivestudy
AT madhishabira 2855respiratorysyncytialvirusneutralizingantibodiesincordbloodandserumfrominfantsupto2yearsofageinamultinationalprospectivestudy
AT maleuxkoen 2855respiratorysyncytialvirusneutralizingantibodiesincordbloodandserumfrominfantsupto2yearsofageinamultinationalprospectivestudy
AT lienanhnguyenthi 2855respiratorysyncytialvirusneutralizingantibodiesincordbloodandserumfrominfantsupto2yearsofageinamultinationalprospectivestudy
AT puthanakitthanyawee 2855respiratorysyncytialvirusneutralizingantibodiesincordbloodandserumfrominfantsupto2yearsofageinamultinationalprospectivestudy
AT silaspeter 2855respiratorysyncytialvirusneutralizingantibodiesincordbloodandserumfrominfantsupto2yearsofageinamultinationalprospectivestudy
AT stoszeksoniak 2855respiratorysyncytialvirusneutralizingantibodiesincordbloodandserumfrominfantsupto2yearsofageinamultinationalprospectivestudy
AT tangsathapornpongauchara 2855respiratorysyncytialvirusneutralizingantibodiesincordbloodandserumfrominfantsupto2yearsofageinamultinationalprospectivestudy
AT teeratakulpisarnjamaree 2855respiratorysyncytialvirusneutralizingantibodiesincordbloodandserumfrominfantsupto2yearsofageinamultinationalprospectivestudy
AT virtamiia 2855respiratorysyncytialvirusneutralizingantibodiesincordbloodandserumfrominfantsupto2yearsofageinamultinationalprospectivestudy
AT zamankhalequ 2855respiratorysyncytialvirusneutralizingantibodiesincordbloodandserumfrominfantsupto2yearsofageinamultinationalprospectivestudy